Transgenomic Booted From Nasdaq Capital Market for Failing Listing Requirements | GenomeWeb
NEW YORK (GenomeWeb News) — Transgenomic shares will stop trading on the Nasdaq Capital Market before the opening of business tomorrow for failing to maintain minimum listing requirements, the company said today.
 
The Capital Market notified the company on Feb. 13 that its stock would be delisted for failing to maintain a minimum share price of $1.00. The company said it does not plan to appeal.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.